JP2024541402A5 - - Google Patents

Info

Publication number
JP2024541402A5
JP2024541402A5 JP2024529294A JP2024529294A JP2024541402A5 JP 2024541402 A5 JP2024541402 A5 JP 2024541402A5 JP 2024529294 A JP2024529294 A JP 2024529294A JP 2024529294 A JP2024529294 A JP 2024529294A JP 2024541402 A5 JP2024541402 A5 JP 2024541402A5
Authority
JP
Japan
Prior art keywords
sequence
nuclease system
ribonucleic acid
manipulated
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024529294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541402A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/080437 external-priority patent/WO2023097282A1/en
Publication of JP2024541402A publication Critical patent/JP2024541402A/ja
Publication of JP2024541402A5 publication Critical patent/JP2024541402A5/ja
Pending legal-status Critical Current

Links

JP2024529294A 2021-11-24 2022-11-23 エンドヌクレアーゼ系 Pending JP2024541402A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163282999P 2021-11-24 2021-11-24
US63/282,999 2021-11-24
US202163289981P 2021-12-15 2021-12-15
US63/289,981 2021-12-15
US202263356908P 2022-06-29 2022-06-29
US63/356,908 2022-06-29
PCT/US2022/080437 WO2023097282A1 (en) 2021-11-24 2022-11-23 Endonuclease systems

Publications (2)

Publication Number Publication Date
JP2024541402A JP2024541402A (ja) 2024-11-08
JP2024541402A5 true JP2024541402A5 (enExample) 2025-12-01

Family

ID=86540394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024529294A Pending JP2024541402A (ja) 2021-11-24 2022-11-23 エンドヌクレアーゼ系

Country Status (8)

Country Link
US (2) US12410449B2 (enExample)
EP (1) EP4437096A4 (enExample)
JP (1) JP2024541402A (enExample)
KR (1) KR20240110603A (enExample)
AU (1) AU2022396533A1 (enExample)
CA (1) CA3234233A1 (enExample)
MX (1) MX2024006257A (enExample)
WO (1) WO2023097282A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119452085A (zh) 2021-08-27 2025-02-14 宏基因组学公司 具有ruvc结构域的酶
KR20240110603A (ko) 2021-11-24 2024-07-15 메타지노미, 인크. 엔도뉴클레아제 시스템
CN121241133A (zh) * 2023-03-31 2025-12-30 阿伯生物技术公司 Crispr核酸酶多肽和包含此类crispr核酸酶多肽的基因编辑系统
WO2025117544A1 (en) * 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
CN117384884B (zh) * 2023-11-30 2024-03-08 辉大(上海)生物科技有限公司 IscB多肽及其用途
CN117511912B (zh) * 2023-12-22 2024-03-29 辉大(上海)生物科技有限公司 IscB多肽、包含其的系统及其用途
WO2025207709A1 (en) * 2024-03-26 2025-10-02 Arbor Biotechnologies, Inc. Reverse transcription-mediated gene editing systems and uses thereof
WO2026044118A1 (en) * 2024-08-21 2026-02-26 Metagenomi, Inc. Endonuclease systems
WO2026073121A2 (en) * 2024-09-30 2026-04-02 Arbor Biotechnologies, Inc. Compact gene editors for delivery by adeno-associated viral vectors

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291438B1 (en) 1993-02-24 2001-09-18 Jui H. Wang Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use
US5858988A (en) 1993-02-24 1999-01-12 Wang; Jui H. Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
DK3363902T3 (da) 2012-12-06 2020-01-02 Sigma Aldrich Co Llc Crispr-baseret genommodifikation og -regulering
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
US10584358B2 (en) 2013-10-30 2020-03-10 North Carolina State University Compositions and methods related to a type-II CRISPR-Cas system in Lactobacillus buchneri
WO2015089364A1 (en) 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
MX2017014560A (es) 2015-05-15 2018-03-01 Pioneer Hi Bred Int Caracterizacion rapida de sistemas de endonucleasa cas, secuencias pam y elementos arn de guia.
US10392607B2 (en) 2015-06-03 2019-08-27 The Regents Of The University Of California Cas9 variants and methods of use thereof
US20160362667A1 (en) 2015-06-10 2016-12-15 Caribou Biosciences, Inc. CRISPR-Cas Compositions and Methods
EP3929287A3 (en) 2015-06-18 2022-04-13 The Broad Institute, Inc. Crispr enzyme mutations reducing off-target effects
WO2016205759A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
EP3390632B1 (en) 2015-12-18 2025-09-10 Danisco US Inc. Methods and compositions for polymerase ii (pol-ii) based guide rna expression
MX2018010484A (es) 2016-03-04 2019-01-10 Editas Medicine Inc Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
EP3426780A1 (en) 2016-03-11 2019-01-16 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
WO2018035250A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
WO2018041120A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
CA3038982A1 (en) 2016-09-30 2018-04-05 The Regents Of The University Of California Rna-guided nucleic acid modifying enzymes and methods of use thereof
WO2018074979A1 (en) 2016-10-17 2018-04-26 Nanyang Technological University Truncated crispr-cas proteins for dna targeting
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
WO2018209712A1 (en) 2017-05-19 2018-11-22 Tsinghua University Engineering of a minimal sacas9 crispr/cas system for gene editing and transcriptional regulation optimized by enhanced guide rna
CN110168078B (zh) 2017-01-06 2024-05-14 免疫生物公司 具有降低的cd96/tigit表达的遗传修饰的nk-92细胞
MX2019011215A (es) 2017-03-24 2020-02-12 Curevac Ag Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos.
CN110892069B (zh) 2017-03-30 2024-02-09 国立大学法人京都大学 基于基因组编辑的外显子跳跃诱导方法
BR112019023608A2 (pt) 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
CN107164377A (zh) 2017-06-12 2017-09-15 王小平 基于碱基编辑的基因敲除方法及其应用
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10253365B1 (en) 2017-11-22 2019-04-09 The Regents Of The University Of California Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs
WO2019161290A1 (en) 2018-02-15 2019-08-22 Sigma-Aldrich Co. Llc Engineered cas9 systems for eukaryotic genome modification
KR20200124702A (ko) 2018-02-23 2020-11-03 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 신규한 cas9 오르소로그
CA3093919A1 (en) 2018-03-15 2019-09-19 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
EP3775213A1 (en) 2018-04-13 2021-02-17 Sigma Aldrich Co. LLC Modification of immune-related genomic loci using paired crispr nickase ribonucleoproteins
WO2020041120A1 (en) 2018-08-20 2020-02-27 Massachusetts Institute Of Technology Robotic manipulation of objects using external contacts
WO2020055941A1 (en) * 2018-09-13 2020-03-19 Excision Biotherapeutics, Inc. Compositions and methods for excision with single grna
CN110904045A (zh) 2018-09-17 2020-03-24 中国科学院动物研究所 经修饰的t细胞、其制备方法及用途
CA3116132A1 (en) 2018-10-16 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for immunotherapy
KR20210116526A (ko) 2019-01-16 2021-09-27 빔 테라퓨틱스, 인크. 증진된 항-신생물 활성 및 면역억제 내성을 갖는 변형된 면역 세포
US12600971B2 (en) 2019-02-13 2026-04-14 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
KR20240007322A (ko) 2019-02-14 2024-01-16 메타지노미, 인크. Ruvc 도메인이 존재하는 효소
CN113728097A (zh) 2019-02-14 2021-11-30 宏基因组学知识产权技术有限责任公司 具有ruvc结构域的酶
US20220220460A1 (en) 2019-02-14 2022-07-14 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
JP2020154564A (ja) 2019-03-19 2020-09-24 富士通株式会社 学習方法、学習プログラムおよび学習装置
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
US20220403357A1 (en) 2019-11-12 2022-12-22 The Broad Institute, Inc. Small type ii cas proteins and methods of use thereof
CA3177051A1 (en) 2020-03-31 2021-10-07 Metagenomi, Inc. Class ii, type ii crispr systems
WO2021202559A1 (en) * 2020-03-31 2021-10-07 Metagenomi Ip Technologies, Llc Class ii, type ii crispr systems
CN116096892A (zh) 2020-05-08 2023-05-09 宏基因组学公司 具有RuvC结构域的酶
WO2021226369A1 (en) 2020-05-08 2021-11-11 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
CA3192224A1 (en) 2020-09-11 2022-03-17 Jyun-Liang LIN Base editing enzymes
CN112126661B (zh) 2020-09-30 2022-07-22 上海中医药大学 一种高效敲除nk细胞中tigit基因的方法
EP4203993A4 (en) 2020-10-23 2024-10-23 The Broad Institute, Inc. Reprogrammable iscb nucleases and uses thereof
JP7877351B2 (ja) 2021-03-19 2026-06-22 メタゲノミ セラピューティクス,インク. Cas酵素を用いたマルチプレックス編集
EP4330386A4 (en) 2021-04-30 2025-05-14 Metagenomi, Inc. Enzymes with ruvc domains
KR20240110603A (ko) 2021-11-24 2024-07-15 메타지노미, 인크. 엔도뉴클레아제 시스템
WO2023097262A1 (en) 2021-11-24 2023-06-01 Metagenomi, Inc. Endonuclease systems

Similar Documents

Publication Publication Date Title
JP2023519953A5 (enExample)
JP2023517041A5 (enExample)
JP2022520428A5 (enExample)
JP2023540797A5 (enExample)
JP2024535672A5 (enExample)
GB2605340A (en) Base editing enzymes
KR102168489B1 (ko) CRISPR/Cpf1 시스템을 이용한 유전체 편집용 조성물 및 이의 용도
CA3128755C (en) Compositions and methods for treating hemoglobinopathies
AU2020223370B2 (en) Enzymes with RuvC domains
GB2608292A (en) Class II, type II CRISPR systems
GB2625500A (en) Engineered CasX repressor systems
US9834774B2 (en) Methods and compositions for rapid seamless DNA assembly
US11149302B2 (en) Method of DNA synthesis
JP2023541400A5 (enExample)
JP2023516226A5 (enExample)
JP2024511163A5 (enExample)
EP2929027A1 (en) Molecular fabrication
JPH04108385A (ja) 均一化cDNAライブラリーの作製法
JP2023533417A5 (enExample)
JP2024517607A5 (enExample)
JP2025504898A5 (enExample)
Yin et al. Non-canonical inhibition strategies and structural basis of anti-CRISPR proteins targeting type I CRISPR-Cas systems
JP2023543351A5 (enExample)
WO2022232638A2 (en) Enzymes with ruvc domains
JP2023542976A5 (enExample)